Texas is currently home to 4877 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
Recruiting
This study will probe if the biological changes in amnestic mild cognitive impairment (aMCI) are related to a history of mild traumatic brain injury (mTBI) using high definition transcranial direct current stimulation (HD-tDCS) and blood-derived biomarker tools. Participants who Do as well as those who Do Not have a history of mTBI will be enrolled in the study.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/01/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Amnestic Mild Cognitive Impairment, Mild Traumatic Brain Injury, Concussion, Brain
A Mobile Phone Text-based Intervention to Reduce Sedentary Behavior and Engage Communities on the Importance of Healthy Lifestyles: the TEXT2MOVE Study
Recruiting
To learn if an 8-week, phone-based texting intervention program will reduce sedentary (non-mobile) behavior.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Life Style, Healthy Lifestyle
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Recruiting
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
05/01/2025
Locations: Saint Joseph Regional Cancer Center, Bryan, Texas
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
Recruiting
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusin... Read More
Gender:
ALL
Ages:
Between 70 years and 95 years
Trial Updated:
05/01/2025
Locations: Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas
Conditions: Aging
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
05/01/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: B-cell Acute Lymphoblastic Leukemia
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
Recruiting
The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI) therapy in participants with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: START San Antonio, San Antonio, Texas
Conditions: Advanced Solid Tumors
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
Recruiting
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 3 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
04/30/2025
Locations: Proactive RGV LLC, Brownsville, Texas
Conditions: Pneumococcal Vaccines
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
Recruiting
To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic therapy. To learn if using SRS to treat all brain metastases that do not respond to systemic therapy versus treating only metastases that are getting worse can help to control CNS disease in patients whose disease gets worse after systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
Recruiting
This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal antibody-cleavable peptide linker-exatecan) as monotherapy. Part B (Cohort Expansion) is intended to further characterize the safety and preliminary clinical activity profile of the RP2D of OBI-992 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Recruiting
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.
Gender:
FEMALE
Ages:
Between 14 years and 35 years
Trial Updated:
04/30/2025
Locations: University of Texas, Houston, Houston, Texas
Conditions: Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
AltaValve Pivotal Trial
Recruiting
This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Recruiting
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery. Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid. Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young... Read More
Gender:
ALL
Ages:
Between 5 years and 30 years
Trial Updated:
04/30/2025
Locations: MD Anderson Main Campus, Houston, Texas
Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults